Comparison of ceftizoxime and cefazolin in respiratory tract infection —the second report ceftizoxime 2g vs cefazolin 4g (well controlled study)

Kenzo Shiot, Fumio Mik, Tomokazu Asa, Kenji Kub, Kenji Takamatsl, Masakazu Kohno, Keizo Beppi, Makoto Murai, Yutaka Osak, Tsugio Tera, Shosaku Abi, Hiroshi Yaguch, Takashi Mikam, Katsuo Suzuki, Yuichi Sasak, Youko Moriyam, Rensuke Kuroda, Kouichi Nasuhara, Jutarou Shimomura, Kazunori HaradaKiyoshi Kond, Hironobl Kakizaki, Shigeo Hasegawa, Yasumichi Kat, Akira Saito, Katsuhiko Matsui, Masumi Tomisawa, Kazuo Takebe, Yoshihiro Kumasaka, Hisashi Nakamata, Shiro Kosaka, Mitsuo Nakamura, Kenichi Imamura, Seiichi Murakami, Kazuo Sasaki, Shijichiro Yoshida, Mitsuaki Yoshioica, Syoko Narita, Kenichi Kimura, Tamotsu Takishima, Sumio Arai, Kiyoshi Konno, Kotaro Oizumi, Akira Watanabe, Seiichi Aonuma, Izumi Hayashi, Tsugushi Ito, Shingo Arai, Shigeo Takizawa, Kunio Imataka, Kenichi Okayama, Masataka Katsu, Keimei Mashimo, Sumio Yamaoka, Keiichi Nakagawa, Yoshiaki Kawaguchi, Hiroaki Nakazawa, Kentaro Watanabe, Masaru Koyama, Hiroyuki Kobayashi, Junzaburo Kabe, Mikihisa Suehara, Hiroyoshi Ishibashi, Yutaka Hayakawa, Yoshio Kobayashi, Ippei Fujimori, Hajimu Takeda, Masanaga Takato, Seiko Kawashima, Fusanosuke Yamasaku, Yasutoshi Suzuki, Osamu Sekine, Yoshimaru Usuda, Nobuki Aoki, Yasuko Yuasa, Nobuo Oya, Mitsuru Hayase, Kaoru Ohyama, Kuninori Suzuki, Toshiyuki Yamamoto, Masahito Kato, Hirohiko Nagasaka, Kozo Mor, Saburo Kitaura, Kunio Nanj, Joichi Kato, Toshihiko Takeuchi, Katsutaka Torikai, Mototaka Sugiura, Teruo Katayama, Takashi Kobayashi, Mitsuru Iwakura, Keisuke Nishiwaki, Takahiro Tsujimoto, Kenichi Shimizu, Rinzo Soejima, Toshiharu Matsushima, Yoshihiko Tano, Yoshihito Niki, Yukio Nishimoto, Michio Yamakido, Masao Kuwahara, Kazuaki Takeuchi, Osamu Kurimura, Kazue Sadamoto, Hideo Sasaki, Eiro Tsubura, Yoshihiro Takishita, Tsuneo Ishibashi, Masahiro Takamoto, Masahiko Kamatani, Kohei Hara, Atsushi Saito, Masao Nakatomi, Masaru Nasu, Kinichi Izumikawa, Yoshiteru Shigenc, Rokushi Oka, Masamoto Nakano, Akira Ikebe, Hisashi Ishikawa, Kazuhiro Okuno, Keizo Yamaguchi, Tatsuo Tomita, Norimasa Ohno, Norihiko Nakahara

研究成果: Article査読

1 被引用数 (Scopus)

抄録

The therapeutic efficacy, adverse reactions and usefulness of ceftizoxime (FK 749, CZX) were objectively compared with those of cefazolin (CEZ) in 230 patients with chronic respiratory tract infection or pneumonia in the well controlled study at 33 institutions in Japan. Patients were given daily ceftizoxime 2 g or cefazolin 4 g by i. v. drip infusion for, in principle, 14 days. The results were as follows: 1) No significant difference in therapeutic efficacy was observed between the patients with respiratory tract infection given ceftizoxime 2 g/day and cefazolin 4 g/day. 2) The therapeutic efficacy of ceftizoxime 2 g/day was significantly superior to that of cefazolin 4 g/day except in patients with elevated mycoplasmal antibody and/or cold hemagglutinin titer. 3) The improvement in sputum volume of patients with pneumonia or lung abscess was significantly better in the cefazolin group than in the ceftizoxime group on the 3 rd day of dosing and in patients with respiratory tract infection except pneumonia and lung abscess, on the 14 th day of dosing. 4) The eradication rate of causative organisms isolated from patients was significantly higher in the ceftizoxime group than in the cefazolin group. 5) No significant difference was noted between the two drug groups in incidence of adverse reactions. These findings suggest that the therapeutic efficacy of ceftizoxime 2 g/day on bacterial respiratory tract infection is more excellent than that of cefazolin 4 g/day.

本文言語English
ページ(範囲)994-1043
ページ数50
ジャーナルChemotherapy
29
9
DOI
出版ステータスPublished - 1981
外部発表はい

ASJC Scopus subject areas

  • 薬理学(医学)
  • 感染症
  • 薬理学
  • 創薬
  • 腫瘍学

フィンガープリント

「Comparison of ceftizoxime and cefazolin in respiratory tract infection —the second report ceftizoxime 2g vs cefazolin 4g (well controlled study)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル